GlassScriptPhysician profile
Satish Angra
NPI 1992810550
$7,565.86
in general payments reported to CMS, 2019-2025
31 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $789 · 2021: $1,252 · 2022: $1,234 · 2023: $1,159 · 2024: $986 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,219.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,493.93 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,255.80 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $967.04 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $581.24 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $409.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $336.88 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $320.99 | 2019-2024 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $245.64 | 2019-2021 | |
| Pfizer INC. | $220.26 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $210.01 | 2022-2025 | |
| Cumberland Pharmaceuticals, INC. | $189.55 | 2024-2025 | Kristalose |
| Janssen Pharmaceuticals, INC | $164.10 | 2019-2021 | |
| Inspire Medical Systems, INC. | $142.88 | 2025 | Inspire |
| Allergan, INC. | $142.61 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $137.23 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $113.43 | 2021 | |
| Medtronic, INC. | $109.45 | 2021 | |
| Gilead Sciences, INC. | $86.16 | 2020-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $82.54 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $62.78 | 2021 | |
| Merck Sharp & Dohme LLC | $46.41 | 2019-2021 | |
| Sanofi Pasteur INC. | $36.66 | 2019-2023 | |
| Antares Pharma, INC. | $35.54 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $32.33 | 2024 | Veozah |
| Alexion Pharmaceuticals, INC. | $31.34 | 2025 | Ultomiris |
| Abbott Laboratories | $23.99 | 2022 | |
| Horizon Therapeutics Plc | $20.70 | 2020 | |
| Daiichi Sankyo INC. | $19.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.05 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.43 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $14.34 | 2025 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Angra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.